Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 6/20 | 0.51 |
| ▸ | GNAI3 | P08754 | 5/20 | 0.51 |
| ▸ | GNAI1 | P63096 | 5/20 | 0.51 |
| ▸ | BCHE | P06276 | 5/20 | 0.50 |
| ▸ | HRH2 | P25021 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | GUSB | P08236 | 2/20 | 0.44 |
| ▸ | EBP | Q15125 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16511589 | 0.93 | HRH3 (0.47) | GNAO1GNAI3GNAI1BCHEHRH2 | |
| SCHEMBL13472608 | 0.93 | HRH3 (0.47) | GNAO1GNAI3GNAI1BCHEHRH2 | |
| SCHEMBL19711122 | 0.90 | BCHE (0.58) | GNAO1GNAI3GNAI1BCHEGUSB | |
| SCHEMBL19273640 | 0.89 | GNAO1 (0.59) | GNAO1GNAI3GNAI1BCHEGUSB | |
| SCHEMBL23921893 | 0.89 | GNAO1 (0.59) | GNAO1GNAI3GNAI1BCHEGUSB | |
| SCHEMBL24040198 | 0.89 | GNAO1 (0.59) | GNAO1GNAI3GNAI1BCHEGUSB | |
| Iodide SCHEMBL23001105 | 0.87 | GNAO1 (0.58) | GNAO1GNAI3GNAI1BCHEGUSB | |
| Iodide SCHEMBL23001162 | 0.87 | GNAO1 (0.58) | GNAO1GNAI3GNAI1BCHEGUSB | |
| SCHEMBL11928090 | 0.87 | GNAO1 (0.56) | GNAO1GNAI3GNAI1BCHEGUSB | |
| SCHEMBL12155274 | 0.85 | KDM1A (0.43) | HRH2HRH1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975088-B2 | Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors | INCYTE CORPORATION (US) | 2021-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975088-B2 | Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors | PIK3R5, PIK3CD, PIK3CA | GNAO1 716/4885GNAI3 190/4885GNAI1 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.